Accrued contingent consideration for Libtayo intangible asset Noncash or Part Noncash Acquisition, Intangible Assets Acquired Maturities within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Repurchases of Common Stock (in shares) Stock Repurchased During Period, Shares Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Unrestricted Unrestricted [Member] Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements. Income tax expense Income Tax Expense (Benefit) Milestone Type [Domain] Milestone Type [Domain] Milestone Type [Domain] Geographical [Domain] Geographical [Domain] Deferred tax assets Deferred Income Tax Assets, Net Fair Value and Unrealized Losses of Marketable Securities Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Preferred Stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Statements of Operations Income Statement [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additional Paid-in Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus November 2021 Share Repurchase Program Share Repurchase Program, November 2021 [Member] Share Repurchase Program, November 2021 Cost of goods, collaboration and contract manufacturing Cost of Goods and Services Sold Weighted average shares outstanding - diluted (in shares) Weighted average shares - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Preferred Stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Number of IPR filed Number of Inter Parties Review (IPR) Petitions Filed Number of Inter Parties Review (IPR) Petitions Filed Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Receivable [Domain] Receivable [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] '226 and '992 Patents '226 Patent And '992 Patent [Member] '226 Patent And '992 Patent Regeneron's share of profits in connection with commercialization Share Of Profit (Losses) In Connection With Commercialization [Member] Share Of Profit (Losses) In Connection With Commercialization [Member] Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Share Repurchase Program, January 2023 Share Repurchase Program, January 2023 [Member] Share Repurchase Program, January 2023 Restricted Restricted [Member] Restricted [Member] Financial Instruments [Domain] Financial Instruments [Domain] Inmazeb Inmazeb [Member] Inmazeb Sonoma Biotherapeutics, Inc. Sonoma Biotherapeutics, Inc. [Member] Sonoma Biotherapeutics, Inc. Statistical Measurement [Domain] Statistical Measurement [Domain] Other operating (income) expense, net Other Operating Income (Expense), Net Antidilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of assets measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Sales or maturities of marketable and other securities Proceeds from Sale and Maturity of Marketable Securities Legal Matters Legal Matters and Contingencies [Text Block] Preferred Stock, shares authorized (in shares) Preferred Stock, Shares Authorized Development Milestone Development Milestone [Member] Development Milestone Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Other non-cash items, net Other Noncash Income (Expense) Property, plant, and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Current liabilities: Liabilities, Current [Abstract] Common Stock, shares issued (in shares) Common Stock, Shares, Issued Total cost of shares Treasury Stock, Value, Acquired, Cost Method Concentration Risk [Line Items] Concentration Risk [Line Items] Net income Net income Net income - basic and diluted Net Income (Loss) Attributable to Parent Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Deferred revenue Contract with Customer, Liability, Current Maturities after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Stock options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Subsequent Event Type [Axis] Subsequent Event Type [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value - Total Debt Securities, Available-for-Sale, Unrealized Loss Position Milestone Type [Axis] Milestone Type [Axis] Milestone Type Equity Component [Domain] Equity Component [Domain] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Subsequent Event Type [Domain] Subsequent Event Type [Domain] Assets, Fair Value Disclosure, Total Assets, Fair Value Disclosure Sales-based milestones earned Sales-Based Milestone Earned [Member] Sales-Based Milestone Earned Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Other operating income Other Operating Income (Expense) [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Revenue, remaining performance obligation, variable consideration amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Cost of collaboration and contract manufacturing Collaboration and Contract Manufacturing [Member] Collaboration and Contract Manufacturing [Member] McKesson Corporation McKesson Corporation [Member] McKesson Corporation [Member] Evkeeza Evkeeza [Member] Evkeeza Maturities after five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Treasury Stock, at cost; 23.5 shares in 2023 and 22.6 shares in 2022 Treasury Stock, Common, Value Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other noncurrent assets Other Assets, Noncurrent Fair Value Total Available-for-sale debt securities Debt Securities, Available-for-Sale Payments for Libtayo intangible asset Payments To Acquire Intangible Assets1 Payments To Acquire Intangible Assets1 Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Libtayo LIBTAYO Net Product Sales [Member] LIBTAYO Net Product Sales [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Project [Axis] Project [Axis] Counterparty Name [Axis] Counterparty Name [Axis] One-time payment in connection with change in Japan arrangement One-time Payment in Connection With Change in Japan Arrangement [Member] One-time Payment in Connection With Change in Japan Arrangement Reimbursement for manufacturing of ex-U.S. commercial supplies Reimbursement For Manufacturing Of ex-Commercial Supplies [Member] Reimbursement For Manufacturing Of ex-Commercial Supplies Gross product revenue Gross Product Revenue [Member] Gross Sales Revenue [Member] Award Type [Axis] Award Type [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] EYLEA EYLEA Net Product Sales [Member] Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions. Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Regeneron's share of profits in connection with commercialization of EYLEA outside the United States Net Profit In Connection With Commercialization [Member] Net Profit In Connection With Commercialization [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Available-for-sale Debt Securities Debt Securities, Available-for-Sale [Table Text Block] Statement of Cash Flows Cash Flow, Supplemental Disclosures [Text Block] Cash and Cash Equivalents [Abstract] Entities [Table] Entities [Table] Issuance/distribution of Common Stock for 401(k) Savings Plan Stock Issued/Distributed During Period, Value, Employee Benefit Plan Stock Issued/Distributed During Period, Value, Employee Benefit Plan Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Stock options Share-Based Payment Arrangement, Option [Member] Expenses: Costs and Expenses [Abstract] Legal Entity [Axis] Legal Entity [Axis] Other (expense) income, net Other Nonoperating Income (Expense) Long-term debt Long-Term Debt, Excluding Current Maturities Common Stock, shares authorized (in shares) Common Stock, Shares Authorized Certificates of deposit Certificates of deposit Certificates of Deposit [Member] Total liabilities Liabilities Percentage share of profits to reimburse collaborating party Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Geographical [Axis] Geographical [Axis] Maximum Maximum [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Class A Stock Common Class A [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Ronapreve Ronapreve [Member] Ronapreve Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value (Decrease) increase in deferred revenue Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Preferred Stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Entity Small Business Entity Small Business Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Revenues: Revenues [Abstract] Percentage of trial costs required to be funded by collaborating party Percentage of Trial Costs Required To Be Funded By Collaborating Party Percentage of Trial Costs Required To Be Funded By Collaborating Party Restricted cash included in Other noncurrent assets Restricted Cash Sales-Based Milestones Sales-Based Milestones [Member] Sales-Based Milestones Royalty payment to collaborating party, percentage of net product sales Royalty Payment to Collaborating Party, Percentage of Net Product Sales Royalty Payment to Collaborating Party, Percentage of Net Product Sales Period for achieving sales target for milestone payment, rolling basis Period for Achieving Sales Target for Milestone Payment, Rolling Basis Period for Achieving Sales Target for Milestone Payment, Rolling Basis Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Schedules of sales to customers as percentage of total gross product revenue Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Summary of Non-Cash Investing and Financing Activities Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Classification of Investment [Axis] Classification of Investment [Axis] This element represents the general categories of investments, which may be classified as Unrestricted or Restricted. Concentration Risk [Table] Concentration Risk [Table] Financial Instrument [Axis] Financial Instrument [Axis] Decrease in accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Interim Financial Statements Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Besse Medical, a subsidiary of AmerisourceBergen Corporation Besse Medical [Member] Besse Medical [Member] Subsequent Event Subsequent Event [Member] Sales Milestone Three Sales Milestone Three [Member] Sales Milestone Three Schedule of accounts receivable and deferred revenue information Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Sales-Based Milestone Two Sales-Based Milestone Two [Member] Sales-Based Milestone Two Total Expenses Costs and Expenses Other revenue Product and Service, Other [Member] Sovereign bonds Sovereign bonds Sovereign Debt Securities [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Class of Stock [Line Items] Class of Stock [Line Items] Unrealized Loss - Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Total assets Assets '631 Patent '631 Patent [Member] '631 Patent SG&A expense Selling, General and Administrative Expenses [Member] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Levels of twelve-month sales at which sales milestone payments would be received Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received Unrealized Loss - 12 Months or Greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Equity securities Equity Securities, FV-NI, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Trade accounts receivable Trade Accounts Receivable [Member] LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortized Cost Basis Debt Securities, Available-for-Sale, Amortized Cost Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Sales Milestone Five Sales Milestone Five [Member] Sales Milestone Five Long-term debt fair value Long-Term Debt, Fair Value Share repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Inventories Total Inventories Inventory, Net Asset-backed securities Asset-Backed Securities [Member] Accounts payable Accounts Payable, Current Statements of Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Net Income Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Marketable Securities, Based on Contractual Maturity Dates Investments Classified by Contractual Maturity Date [Table Text Block] Finance lease liabilities Finance Lease, Liability, Noncurrent Sanofi Sanofi [Member] Sanofi Entity Filer Category Entity Filer Category Proceeds from issuance of Common Stock Proceeds from Issuance of Common Stock Weighted average shares outstanding - basic (in shares) Weighted average shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Award Type [Domain] Award Type [Domain] Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses Regeneron's Obligation Of Research And Development Expenses, Net of Reimbursement Of Research And Development Expenses [Member] Regeneron's Obligation Of Research And Development Expenses, Net of Reimbursement Of Research And Development Expenses Unrealized Loss - Total Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Up-front payment to collaborating party Up-Front Payment to Collaborating Party Up-Front Payment to Collaborating Party U.S. UNITED STATES Roche Collaboration Agreement Roche Collaboration Agreement [Member] Roche Collaboration Agreement Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Total adjustments Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none Preferred Stock, Value, Issued Restricted stock awards and restricted stock units Restricted Stock [Member] Reimbursement for manufacturing of commercial supplies Reimbursement for manufacturing of ex-U.S. commercial supplies Reimbursement For Manufacturing Of Commercial Supplies [Member] Reimbursement For Manufacturing Of Commercial Supplies [Member] Revenues Up-front payment to be made to collaborator Revenue from Contract with Customer, Excluding Assessed Tax Corporate bonds Corporate bonds Corporate bonds Corporate Bond Securities [Member] Entity Address, City or Town Entity Address, City or Town Amounts recognized in connection with up-front payments received Amounts Recognized In Connection With Up-Front Payments [Member] Amounts Recognized In Connection With Up-Front Payments [Member] Percentage of share of profits used to reimburse collaborating party for trial costs Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs Cover [Abstract] Cover [Abstract] Sales-Based Milestone One Sales-Based Milestone One [Member] Sales-Based Milestone One Legal Matters Legal Costs, Policy [Policy Text Block] Work-in-process Inventory, Work in Process, Net of Reserves Minimum Minimum [Member] Deferred income taxes Increase (Decrease) in Deferred Income Taxes Losses on marketable and other securities, net Marketable and Other Securities, Gain (Loss) Marketable and Other Securities, Gain (Loss) Product Sales Revenue from Contract with Customer [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Reimbursement of R&D expenses Reimbursement Of Research And Development Expenses [Member] Reimbursement Of Research And Development Expenses [Member] Common Stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Collaboration revenue Collaboration Revenue [Member] Collaboration Revenue Treasury Stock Treasury Stock, Common [Member] Fair Value Measurements Fair Value Disclosures [Text Block] Classification of Investment [Domain] Classification of Investment [Domain] Provides general categories of investments for which information is required or determined to be disclosed. Payments in connection with Common Stock tendered for employee tax obligations Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders' equity Liabilities and Equity Trading Symbol Trading Symbol Entity File Number Entity File Number Praluent Praluent Net Product Sales [Member] Praluent Net Product Sales Treasury stock (in shares) Beginning Balance, treasury (in shares) Ending Balance, treasury (in shares) Treasury Stock, Common, Shares Reimbursement of commercialization-related expenses Reimbursement Of Commercialization-Related Expenses [Member] Reimbursement Of Commercialization-Related Expenses Deferred revenue Contract with Customer, Liability, Noncurrent Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Research and development Research and Development Expense Outside United States Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Entity Information [Line Items] Entity Information [Line Items] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Current Fiscal Year End Date Current Fiscal Year End Date Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Marketable securities Marketable Securities, Current Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Net income per share - diluted (in dollars per share) Earnings Per Share, Diluted Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Bayer Bayer Collaboration Agreement [Member] Bayer Collaboration Agreement [Member] Stock-based compensation charges APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration risk, percentage Concentration Risk, Percentage Concentration Risk Type [Axis] Concentration Risk Type [Axis] Unrealized gain on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Total current liabilities Liabilities, Current Deferred costs Other Inventory, Net of Reserves Sonoma Biotherapeutics, Inc. Collaboration Agreement Sonoma Biotherapeutics, Inc. Collaboration Agreement [Member] Sonoma Biotherapeutics, Inc. Collaboration Agreement Celltrion, Inc. Celltrion, Inc. [Member] Celltrion, Inc. Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Increase (decrease) in accounts payable, accrued expenses, and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Taxes Income Tax Disclosure [Text Block] Customer concentration risk Customer Concentration Risk [Member] Finished goods Inventory, Finished Goods, Net of Reserves Fair Value - 12 Months or Greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Regulatory Milestone Regulatory Milestone [Member] Regulatory Milestone (R&D expense)/Reduction of R&D expense Research And Development Expenses And Reduction of Research And Development Expense [Member] Research And Development Expenses And Reduction of Research And Development Expense Net income per share - basic (in dollars per share) Earnings Per Share, Basic Share Repurchase Program [Axis] Share Repurchase Program [Axis] Other income (expense): Nonoperating Income (Expense) [Abstract] Losses on marketable and other securities, net Equity Securities, FV-NI, Unrealized Gain (Loss) ROW Rest Of World [Member] Rest Of World Entity Address, Address Line One Entity Address, Address Line One Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Deferred revenue Contract with Customer, Liability Total stockholders' equity Beginning Balance Ending Balance Stockholders' Equity Attributable to Parent Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Apotex Inc. Apotex Inc. [Member] Apotex Inc. Interest expense Interest Expense Entity Interactive Data Current Entity Interactive Data Current Unrealized gain (loss) on debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventory valuation reserves Inventory Valuation Reserves Inventories Inventory Disclosure [Text Block] Equity [Abstract] Equity [Abstract] Retained Earnings Retained Earnings [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Common Stock Common Stock Common Stock Common Stock [Member] Receivable Type [Axis] Receivable Type [Axis] Issuance of Common Stock for equity awards granted under long-term incentive plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Project [Domain] Project [Domain] Cost of goods sold Cost Of Goods Sold [Member] Cost Of Goods Sold Repurchases of Common Stock Payments for Repurchase of Common Stock Class of Stock [Axis] Class of Stock [Axis] Statement [Table] Statement [Table] Regeneron's obligation for its share of Sanofi commercial expenses Regeneron's Share Of Commercial Expenses [Member] Regeneron's Share Of Commercial Expenses Schedule of product sales Schedule of collaborative revenue Disaggregation of Revenue [Table Text Block] Sanofi Collaboration Agreement, Antibody Sanofi Collaboration Agreement, Antibody [Member] Sanofi Collaboration Agreement, Antibody [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Marketable securities Marketable Securities, Noncurrent Document Quarterly Report Document Quarterly Report '338 Patent And '069 Patent '338 Patent And '069 Patent [Member] '338 Patent And '069 Patent Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Current assets: Assets, Current [Abstract] Schedule of Shares Repurchased Class of Treasury Stock [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Number of shares (in shares) Treasury Stock, Shares, Acquired Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Retained earnings Retained Earnings (Accumulated Deficit) Commercial paper Commercial paper Commercial Paper [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Purchases of marketable and other securities Payments to Acquire Marketable Securities Entity Central Index Key Entity Central Index Key U.S. government and government agency obligations U.S. government and government agency obligations U.S. government and government agency obligations US Treasury and Government [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Equity Components [Axis] Equity Components [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Measured on a recurring basis Fair Value, Recurring [Member] Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Collaboration, License, and Other Agreements Collaborative Arrangement Disclosure [Text Block] Fair Value - Less than 12 Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Document Fiscal Year Focus Document Fiscal Year Focus Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity [Domain] Entity [Domain] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] City Area Code City Area Code ASSETS Assets [Abstract] Statement [Line Items] Statement [Line Items] Total other income (expense) Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] EYLEA EYLEA Aflibercept Injection [Member] EYLEA Aflibercept Injection Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general, and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Sanofi Collaboration Agreement, Immuno-oncology Sanofi Collaboration Agreement, Immuno-oncology Sanofi Collaboration Agreement, Immuno-oncology [Member] Sanofi Collaboration Agreement, Immuno-oncology [Member] Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits Sanofi's Share of Libtayo U.S. Gross Profits [Member] Sanofi's Share of Libtayo U.S. Gross Profits [Member] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Net product sales Product [Member] Repurchases of Common Stock Stock Repurchased During Period, Value Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Other noncurrent liabilities Other Liabilities, Noncurrent Capital expenditures Payments to Acquire Productive Assets Document Transition Report Document Transition Report Local Phone Number Local Phone Number Acquired in-process research and development Acquired In-Process Research and Development Acquired In-Process Research and Development Income from operations Operating Income (Loss) (R&D expense)/Reduction of R&D expense Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Increase in inventories Increase (Decrease) in Inventories Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Number of ex parte reexamination requests Loss Contingency, Ex Parte Reexamination, Filed, Number Loss Contingency, Ex Parte Reexamination, Filed, Number Securities owned not readily marketable Equity Securities without Readily Determinable Fair Value, Amount Increase in prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Common Stock, shares outstanding (in shares) Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Outstanding Purchase of preferred stock Payments to Acquire Interest in Subsidiaries and Affiliates Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&D Expenses [Member] Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&D Expenses Customer [Domain] Customer [Domain]